The number of years lived with obesity is directly associated with the risk of mortality. This needs to be taken into account when estimating its burden on mortality.
Objective: The evidence for the association between obesity and the risk of type 2 diabetes has been derived mainly from the analysis of the degree of obesity. The role of the duration of obesity as an independent risk has not been fully explored. The objective of the present study was to investigate the association between the duration of obesity and the risk of type 2 diabetes. Design: Prospective cohort study. Setting: The Framingham Heart Study (FHS), follow-up from 1948 to 1998. Subjects: A total of 1256 FHS participants who were free from type 2 diabetes at baseline, but were obese on at least two consecutive of the study's twenty-four biennial examinations, were included. Type 2 diabetes status was collected throughout the 48 years of follow-up of the study. The relationship between duration of obesity and type 2 diabetes was analysed using time-dependent Cox models, adjusting for a number of covariates. Results: The unadjusted hazard ratio (HR) for the risk of type 2 diabetes for men was 1?13 (95 % CI 1?09, 1?17) and for women was 1?12 (95 % CI 1?08, 1?16) per additional 2-year increase in the duration of obesity. Adjustment for sociodemographic variables, family history of diabetes, health behaviour and physical activity made little difference to these HR. For women the evidence of a doseresponse relationship was less clear than for men, particularly for women with an older age at obesity onset. Conclusions: The duration of obesity is a relevant risk factor for type 2 diabetes, independent of the degree of BMI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.